IRIS Accounts Production v24.3.2.46 09685506 Board of Directors 1.2.24 31.1.25 31.1.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh096855062024-01-31096855062025-01-31096855062024-02-012025-01-31096855062023-01-31096855062023-02-012024-01-31096855062024-01-3109685506ns14:PoundSterling2024-02-012025-01-3109685506ns10:Director12024-02-012025-01-3109685506ns10:PrivateLimitedCompanyLtd2024-02-012025-01-3109685506ns10:SmallEntities2024-02-012025-01-3109685506ns10:AuditExempt-NoAccountantsReport2024-02-012025-01-3109685506ns10:SmallCompaniesRegimeForDirectorsReport2024-02-012025-01-3109685506ns10:SmallCompaniesRegimeForAccounts2024-02-012025-01-3109685506ns10:FullAccounts2024-02-012025-01-3109685506ns10:OrdinaryShareClass12024-02-012025-01-3109685506ns10:Director22024-02-012025-01-3109685506ns10:CompanySecretary12024-02-012025-01-3109685506ns10:RegisteredOffice2024-02-012025-01-3109685506ns5:CurrentFinancialInstruments2025-01-3109685506ns5:CurrentFinancialInstruments2024-01-3109685506ns5:ShareCapital2025-01-3109685506ns5:ShareCapital2024-01-3109685506ns5:RetainedEarningsAccumulatedLosses2025-01-3109685506ns5:RetainedEarningsAccumulatedLosses2024-01-3109685506ns5:PlantMachinery2024-01-3109685506ns5:PlantMachinery2024-02-012025-01-3109685506ns5:PlantMachinery2025-01-3109685506ns5:PlantMachinery2024-01-3109685506ns5:WithinOneYearns5:CurrentFinancialInstruments2025-01-3109685506ns5:WithinOneYearns5:CurrentFinancialInstruments2024-01-3109685506ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2025-01-3109685506ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-01-3109685506ns5:CurrentFinancialInstruments2024-02-012025-01-3109685506ns10:OrdinaryShareClass12025-01-31
REGISTERED NUMBER: 09685506













Financial Statements

For The Year Ended 31 January 2025

for

EIMAN PHARMA LIMITED

EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)






Contents of the Financial Statements
For The Year Ended 31 January 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


EIMAN PHARMA LIMITED

Company Information
For The Year Ended 31 January 2025







DIRECTORS: M A Khan
Mrs R Khan





SECRETARY: M A Khan





REGISTERED OFFICE: 79 College Road
Harrow
Middlesex
HA1 1BD





REGISTERED NUMBER: 09685506





ACCOUNTANTS: Ayman Tyler Associates
Accountants & Tax Advisers
79 College Road
Harrow
Middlesex
HA1 1BD

EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)

Balance Sheet
31 January 2025

31.1.25 31.1.24
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 477 939

CURRENT ASSETS
Debtors 5 16,726,685 15,399,590
Cash at bank 2,641,944 4,923,878
19,368,629 20,323,468
CREDITORS
Amounts falling due within one year 6 175,285 1,076,150
NET CURRENT ASSETS 19,193,344 19,247,318
TOTAL ASSETS LESS CURRENT
LIABILITIES

19,193,821

19,248,257

CAPITAL AND RESERVES
Called up share capital 7 400 400
Retained earnings 19,193,421 19,247,857
SHAREHOLDERS' FUNDS 19,193,821 19,248,257

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)

Balance Sheet - continued
31 January 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 February 2025 and were signed on its behalf by:





M A Khan - Director


EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)

Notes to the Financial Statements
For The Year Ended 31 January 2025

1. STATUTORY INFORMATION

EIMAN PHARMA LIMITED is a private company, limited by shares , registered in Not specified/Other. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Investments in associates
Investments in associate undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)

Notes to the Financial Statements - continued
For The Year Ended 31 January 2025

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 February 2024
and 31 January 2025 1,402
DEPRECIATION
At 1 February 2024 463
Charge for year 462
At 31 January 2025 925
NET BOOK VALUE
At 31 January 2025 477
At 31 January 2024 939

5. DEBTORS
31.1.25 31.1.24
£    £   
Amounts falling due within one year:
Other debtors 2,723,035 1,410,790

Amounts falling due after more than one year:
Other debtors 14,003,650 13,988,800

Aggregate amounts 16,726,685 15,399,590

Other debtors balance due within 1 year includes £1,562,025 loaned to Eiman Investments Limited, £700,000 to Everest Pharma Ltd, £300,010 to P Singh, £25,000 to S Juttla, £86,000 to H M Akram & £50,000 to Mahashiv Ltd.

Other Debtors balance of amounts due more than 1year refers to an amount of £14,003,650 of ascertainable deferred consideration to be received on an earn out basis over 3 years..

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.25 31.1.24
£    £   
Other creditors 175,285 1,076,150

Other creditors includes £100,500 due to Wave Pharma Limited.

EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506)

Notes to the Financial Statements - continued
For The Year Ended 31 January 2025

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.1.25 31.1.24
value: £    £   
400 Ordinary 1 400 400

Full details of shareholders are as follows:

132 Ordinary shares held by Mohammad Arsalaan Khan
132 Ordinary shares held by Romana Khan
132 Ordinary shares held by Maaira Khan
4 Ordinary shares held by Wavepharma Limited